Welcome to our dedicated page for Inflarx news (Ticker: IFRX), a resource for investors and traders seeking the latest updates and insights on Inflarx stock.
InflaRx N.V. (Nasdaq: IFRX) is a biopharmaceutical company that regularly issues news on its clinical programs targeting the complement system, particularly the C5a/C5aR axis. Company updates highlight progress with its oral C5a receptor inhibitor izicopan (also referenced as INF904) and its intravenously delivered anti-C5a monoclonal antibody vilobelimab, including GOHIBIC (vilobelimab) for SARS-CoV-2-induced acute respiratory distress syndrome in the European Union.
News about InflaRx often covers clinical trial milestones, such as Phase 2a data in hidradenitis suppurativa and chronic spontaneous urticaria for izicopan, as well as analyses of Phase 3 data for vilobelimab in pyoderma gangrenosum. Releases also describe regulatory interactions, including anticipated discussions with the U.S. Food and Drug Administration, and strategic decisions about prioritizing resources toward izicopan and adjusting spending on GOHIBIC (vilobelimab).
Investors following IFRX news can expect announcements on clinical data readouts, participation in healthcare and investor conferences, and business updates related to funding, cash runway and partnering activities. InflaRx’s communications have included information on BARDA-supported studies in acute respiratory distress syndrome, co-development activities for an anti-C5a antibody in China, and notices regarding Nasdaq listing requirements.
This news feed aggregates InflaRx’s press releases and related coverage so readers can review clinical developments, regulatory updates and corporate actions in one place. For those tracking complement-targeted therapeutics, IFRX news provides insight into how the company is advancing its C5a and C5aR inhibitor programs across dermatologic and respiratory indications and how it is aligning its strategy and capital allocation with these priorities.
InflaRx (Nasdaq: IFRX) announced key management appointments: Thomas Taapken, Ph.D., joins as Chief Financial Officer starting October 1, 2020, and Jordan Zwick is promoted to Chief Strategy Officer. Prof. Niels C. Riedemann emphasized Taapken's extensive biopharmaceutical experience, which will aid the company's late-stage clinical programs, while Zwick's new role aims to enhance U.S. operations. Taapken expressed enthusiasm about leading InflaRx during its first Phase III trial for anti-C5a therapeutics, crucial for addressing chronic inflammatory diseases, including COVID-19 pneumonia.
InflaRx (Nasdaq: IFRX) has initiated the global Phase III trial of IFX-1 for severe COVID-19 pneumonia, with the first site now active in the Netherlands and approval in Germany. The trial aims to enroll approximately 360 critically ill patients and will assess 28-day all-cause mortality as the primary endpoint. Encouraging Phase II results, showing lower mortality and organ dysfunction rates, have been accepted for publication in The Lancet Rheumatology. IFX-1, targeting complement factor C5a, is also being explored for other indications.
InflaRx announced positive results from the Phase II portion of its Phase II/III trial for IFX-1 in COVID-19 pneumonia, showing a 28-day all-cause mortality rate of 13% for treated patients versus 27% in controls. They completed a meeting with the FDA regarding IFX-1 for hidradenitis suppurativa, receiving support for a Phase III program. The company reported cash and equivalents of €98.9 million as of June 30, 2020, and a net loss of €18.3 million, an improvement from €25.1 million in the same period of 2019. Financial metrics indicate reduced research and development expenses.
InflaRx (Nasdaq: IFRX) reported promising initial data from the Phase II trial of IFX-1, showing a 50% lower all-cause mortality rate in patients with severe COVID-19 pneumonia compared to best supportive care. The company plans to advance to a Phase III trial with around 360 patients, aiming for a primary endpoint of 28-day all-cause mortality. The Phase II trial revealed a mortality rate of 13% in the IFX-1 group versus 27% in the control group. Interim analysis for the Phase III trial is expected after enrolling 180 patients.